Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Ellen McLaughlin

Dementia gene raises risk of severe COVID-19

Having a faulty gene linked to dementia doubles the risk of developing severe COVID-19, according to a large-scale study. Researchers at the University of Exeter...

| By Ellen McLaughlin

Genetic-based precision medicine holds promise

A type of personalized care known as precision medicine, and its subset, genomic medicine, is now the standard of care in Connecticut’s Hartford HealthCare Cancer Institute, UConn...

| By Ellen McLaughlin

BioCT stands with BLM

“Black Lives Matter and BioCT is committed to addressing racism through members’ employment practices, their development of therapeutics to benefit all patients and our support of...

| By Ellen McLaughlin

Pfizer establishes new innovation program

Pfizer is establishing the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help provide funding and...

| By Ellen McLaughlin

CT bioscience a leader in fight against COVID-19

As Connecticut continues to face one of the world’s deadliest COVID-19 outbreaks, the state’s bioscience industry has aggressively turned its focus to developing new breakthrough...

| By Ellen McLaughlin

LambdaVision secures funding re artificial retina

LambdaVision has been selected by NASA for a Small Business Innovation Research (SBIR) Phase II award, worth $750,000 over two years. With the continued support...

| By Ellen McLaughlin

InveniAI in strategic partnership with TB Alliance

InveniAI® LLC has formed a strategic partnership with TB Alliance, a non-profit organization dedicated to the discovery, development, and delivery of better, faster-acting and affordable...

| By Ellen McLaughlin

BioCT welcomes Architectural Building Systems

Architectural Building Systems is a multi-generational General Contracting and Construction Management firm that was founded in 1985 to serve the ever-changing needs of customers in...

| By Ellen McLaughlin

101 College St project clears committee hurdle

Plans for a new 10-story, 500,000-square-foot bioscience building in downtown New Haven to feature lab, research, and incubator space have garnered a key approval. The...

| By Ellen McLaughlin

Sema4 and Tangen tackle COVID-19 testing

Tangen Biosciences and LabWare have agreed to enter into an  exclusive partnership whereby LabWare will distribute Tangen’s GeneSpark™ device as part of the LabWare’s Portable Disease...